Pelthos Therapeutics

Yahoo Finance • 2 days ago

Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag

Information technology, industrials and utilities are set to feature prominently in this week’s earnings calendar, with 249 companies scheduled to report. This week’s quant rankings highlight strong momentum among technology and industria... Full story

Yahoo Finance • 3 months ago

Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announce... Full story

Yahoo Finance • 3 months ago

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported every year in the... Full story

Yahoo Finance • 4 months ago

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI u... Full story

Yahoo Finance • 4 months ago

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections cause... Full story

Yahoo Finance • 4 months ago

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a co... Full story

Yahoo Finance • 6 months ago

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patien... Full story

Yahoo Finance • 7 months ago

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1... Full story